Azenta, Inc.
AZTAAzenta, Inc. (AZTA) is a global provider of life science and laboratory automation solutions. The company specializes in research and development services, sample management, and laboratory products, supporting the pharmaceutical, biotech, and healthcare industries. Azenta focuses on enabling scientific discovery through innovative technology and streamlined workflows.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 23, 2021 | $0.10 | 2021-12-02 | 2021-12-03 |
| September 24, 2021 | $0.10 | 2021-09-02 | 2021-09-03 |
| June 25, 2021 | $0.10 | 2021-06-03 | 2021-06-04 |
| March 26, 2021 | $0.10 | 2021-03-04 | 2021-03-05 |
| December 17, 2020 | $0.10 | 2020-12-03 | 2020-12-04 |
Dividends Summary
- Consistent Payer: Azenta, Inc. has rewarded shareholders with 42 dividend payments over the past 10 years.
- Total Returned Value: Investors who held AZTA shares during this period received a total of $3.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.10/share was paid 1492 days ago, on December 23, 2021.
- Yield & Schedule: AZTA currently pays dividends quarterly with an annual yield of 0.99%.
- Dividend Growth: Since 2011, the dividend payout has grown by 25.0%, from $0.08 to $0.10.
- Dividend Reliability: AZTA has maintained or increased its dividend for 42 consecutive payments.
Company News
The biopreservation market is experiencing significant growth driven by healthcare expenditure, research investment, and regenerative medicine, with North America leading and Asia Pacific showing fastest potential expansion. Key challenges include storage logistics and sample transportation standards.
The global biobanking market is projected to reach a valuation of USD 95.5 billion by 2031, growing at a CAGR of 6.8% during the forecast period. The growth is driven by the rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic illnesses worldwide.
The global biobanking market is expected to grow from $72 billion in 2023 to $95.5 billion by 2031, driven by rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic diseases. The disease-based biobanks and population-based biobanks segments are expected to lead the market.
The antibody production market is expected to grow significantly due to the increasing demand for targeted therapies and advancements in biotechnology, such as recombinant DNA technology and high-throughput screening methods.
Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.
